Gilead Sciences | Créances Commerciales



Trade Debtors Changement Date
AbbVie USD 10.92B 553M 2024-12
Agios Pharmaceuticals USD 3.34M 765K 2025-03
ALKERMES USD 321.75M 72.97M 2025-03
Alnylam Pharmaceuticals USD 418.04M 12.73M 2025-03
Amgen USD 8.13B 1.35B 2025-03
Biogen USD 2B 127.7M 2025-03
BioMarin Pharmaceutical USD 739.18M 78.64M 2025-03
Bristol-Myers Squibb USD 14.59B 162M 2025-03
Eli Lilly USD 14B 727.8M 2025-03
Gilead Sciences USD 4.39B 32M 2025-03
GlaxoSmithKline GBP 7.5B 176M 2025-03
Glaxosmithkline GBP 7.32B 542M 2024-12
Incyte USD 823.13M 30.02M 2025-03
J&J USD 16.02B 1.18B 2025-03
Merck USD 11.57B 452M 2025-03
Moderna USD 306M 286M 2025-03
Neurocrine Biosciences USD 479.1M 2M 2024-12
Novartis USD 9B 854M 2024-12
Pfizer USD 14.74B 32M 2025-03
PTC Therapeutics USD 210.5M 51.94M 2025-03
Regeneron Pharmaceuticals USD 5.56B 650.9M 2025-03
Sanofi 447M 10.18B 2025-03
Sarepta Therapeutics USD 724.52M 74.8M 2025-03
United Therapeutics USD 322M 42.7M 2025-03
Vertex Pharmaceuticals USD 1.61B 141.2M 2024-12



Gilead Sciences Créances Commerciales - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.